Mode
Text Size
Log in / Sign up
Phase 4 N=65 Randomized Double-blind Treatment

Efficacy Study of Vaginal Mesh for Anterior Prolapse

Vaginal Prolapse · Uterine Prolapse · Cystocele · Pelvic Organ Prolapse

Enrolled (actual)
65
Serious AEs
7.7%
Results posted
Oct 2020
Primary outcome: Primary: The Primary Outcome Measure for Objective Treatment Success is Anterior Prolapse, Point Ba at Stage 0 or 1 (Defined as Maximal Descent of the Anterior Wall to Greater Than 1 cm Above the Hymen) at One Year. — 12; 10 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
synthetic polypropylene mesh (Device)
Age
Adult, Older Adult · 21+ yrs
Sex
Female
Sponsor
Medstar Health Research Institute
Primary completion
Oct 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
The Primary Outcome Measure for Objective Treatment Success is Anterior Prolapse, Point Ba at Stage 0 or 1 (Defined as Maximal Descent of the Anterior Wall to Greater Than 1 cm Above the Hymen) at One Year.
12; 10

Summary

The primary aim of this double-blind, randomized clinical trial (RCT) is to test the hypothesis that the addition of a standardized technique of interpositional synthetic polypropylene mesh placement improves the one-year outcome of vaginal reconstructive surgery for anterior prolapse compared to traditional vaginal reconstructive surgery without mesh.

Eligibility Criteria

Inclusion Criteria

  • women age > 21
  • diagnosed with stage II-IV vaginal prolapse who desire reconstructive surgery
  • available for 12 months of follow-up
  • able to complete study questionnaires and assessments.
  • available for 12 months follow-up

Exclusion Criteria

  • Uterus in place.
  • No anterior vaginal prolapse.
  • Medical contraindications, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use or a compromised immune system.
  • Current intermittent self catheterization.
  • Pregnancy or desire for future fertility.
  • Presence of an adnexal or ovarian mass.
  • Shortened vagina.
  • Other laparoscopic or abdominal/pelvic surgery in the past 3 months.*
  • Known neurologic or medical condition affecting bladder function, e.g. multiple sclerosis, spinal cord injury.
  • Need for surgery requiring an abdominal incision.
  • <12 months post-partum. (Enrollment can be deferred until time requirement has been met).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00557882). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search